scholarly journals Salivary Duct Carcinoma in the External Auditory Canal Causing Ipsilateral Hearing Loss

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1312
Author(s):  
Shih-Lung Chen ◽  
Chi-Ju Yeh ◽  
Kai-Chieh Chan

Background: Salivary duct carcinoma (SDC) is a rare aggressive tumor. Most tumors are not confined to the salivary ducts; rather, they invade the major and minor salivary glands. Only a few case reports on such tumors in other primary sites have appeared. Case presentation: A 40-year-old male complained of right hearing loss (a common condition), but we made an extremely rare diagnosis of an SDC in the external auditory canal (EAC). EAC cancers are frequently misdiagnosed. In our patient, the otoscope revealed a smooth, bulging subcutaneous lesion with a non-epithelial defect suggestive of a benign lesion. However, an SDC of the EAC was confirmed through pathological and immunohistochemical analysis. Conclusions: We suggest detailed evaluation of even smooth EAC subcutaneous lesions to avoid erroneous diagnoses. To the best of our knowledge, this is the first report of SDC in the EAC.

2001 ◽  
Vol 94 (12) ◽  
pp. 1105-1110 ◽  
Author(s):  
Tsuyoshi KITANISHI ◽  
Hiroya KITANO ◽  
Akira SHIBANO ◽  
Michiko YOSHII ◽  
Tomoya NAGATA ◽  
...  

Pathology ◽  
2008 ◽  
Vol 40 (4) ◽  
pp. 434-437 ◽  
Author(s):  
Tamazin Leecy ◽  
Michael E. Buckland ◽  
Jennifer Turner ◽  
Peter Earls

2021 ◽  
pp. 343-346
Author(s):  
Tsuyoshi Sato ◽  
Takahiro Maeta ◽  
Ryosuke Abe ◽  
Hiroyuki Yamada ◽  
Kazuyuki Ishida ◽  
...  

Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy. A 58-year-old man presented with a right-sided submandibular mass and metastatic lesions in the right supraclavicular and inferior internal jugular nodes. He underwent right submandibulectomy and right neck dissection followed by adjuvant chemoradiotherapy. However, relapse occurred in the hilar lymph node and lumbar spine. Although radiotherapy was performed, a second relapse appeared in the hilar lymph nodes and sacral bone. Immunohistochemical analysis revealed negativity for programmed death ligand-1 (PD-L1) in the primary tumor specimen. The patient then received the anti-programmed death-1 (PD-1) antibody nivolumab. His metastatic lesions were completely eliminated after 48 weeks of therapy. This case reveals that anti-PD-1 antibodies are effective even against PD-L1-negative SDC.


2002 ◽  
Vol 95 (5) ◽  
pp. 493-499
Author(s):  
Tomoko TATEYA ◽  
Hiroyuki KITAMURA ◽  
Shin-ichi TAKAGITA ◽  
Yuka IWAHASHI ◽  
Yasutaka KAWATA ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Deepti Kantamani ◽  
Sai S. Bandaru ◽  
Jennifer L. Miatech ◽  
M. Patrick Stagg

Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,000 patients. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. In this report, we present three cases of SDC. A 71-year-old female with T1N0M0 disease was treated with total parotidectomy, ipsilateral neck dissection, and adjuvant radiotherapy without evidence of disease recurrence at 5 months. The second is a 59-year-old female with TXN1M0 disease who was treated with total parotidectomy with ipsilateral level I-IV neck dissection and adjuvant radiotherapy without evidence of disease occurrence at 21 months. The third case is a 79-year-old male with widely metastatic disease, including brain metastases, treated with cranial irradiation, leuprolide, and lapatinib who remains under home hospice care.


2019 ◽  
Author(s):  
W van Boxtel ◽  
S Lütje ◽  
AC van Engen-van Grunsven ◽  
GW Verhaegh ◽  
JA Schalken ◽  
...  

Author(s):  
Kyung Yeon Kim ◽  
Hae Sang Park ◽  
Sung Min Chung ◽  
Han Su Kim

2019 ◽  
Vol 35 (1) ◽  
pp. 13-20
Author(s):  
Yong Ju Lee ◽  
Yoon Woo Koh ◽  
Sun Och Yoon ◽  
Hyang Joo Ryu ◽  
Hye Ryun Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document